Defense World
15 Aug 2026, 07:33 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Vericel beat quarterly analyst estimates with $0.04 EPS and $77.46 million in revenue, representing 22.5% year-over-year growth. — Positive earnings surprises and strong top-line growth are primary drivers of biotech stock price appreciation.
+0.60Multiple analysts raised their price targets for VCEL in late July, with objectives ranging from $58.00 to $70.00. — Upward revisions of price targets by institutional analysts generally signal bullish sentiment and attract buyers.
+0.50Major institutional investors, including Bank of America, Goldman Sachs, and UBS, increased their positions in Vericel during the first quarter. — Increased accumulation by top-tier financial institutions suggests professional confidence in the company's long-term value.
+0.40Continue reading
6 related stories
Search tags
Corporate insiders sold 52,232 shares totaling over $2.3 million in the last three months, including significant position reductions by Jonathan Siegal and Sean C. Flynn. — Heavy insider selling can be perceived as a lack of confidence in near-term upside or a signal that the stock is reaching a peak.
-0.30Which stocks this story touches
The company beat earnings and revenue estimates, saw increased institutional holdings, and received multiple analyst buy ratings and price target increases.
Mentioned as increasing its stake in VCEL, which is a neutral routine disclosure.
Mentioned as increasing its stake in VCEL, which is a neutral routine disclosure.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
